Ibane Abasolo Olaortua I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module. Institutions of which they are part Head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Biologist Bioquímica Cross-departmental services LinkedIn Twitter Orcid Email Ibane Abasolo Olaortua LinkedIn Twitter Orcid Email Institutions of which they are part Head of group Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Biologist Bioquímica Cross-departmental services I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.
I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB. Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease. I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).
Projects NoCanTher: Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy IP: Simon Schwartz Navarro Collaborators: Ibane Abasolo Olaortua, Joaquin Seras Franzoso, Tamara Del Rio Higueras, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez Funding agency: EUROPEAN COMMISSION Funding: 630633.55 Reference: NOCANTHER_H2020NMP2015 Duration: 01/04/2016 - 30/09/2021 Grup de direccionament i alliberament farmacològic IP: Simon Schwartz Navarro Collaborators: Ibane Abasolo Olaortua, Montse Capella Tomás, José García Arumí, Laura García Latorre, José Raul Herance Camacho Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: Reference: 2014 SGR 1394 Duration: 01/01/2014 - 31/12/2016 Infraestructura IP: Ibane Abasolo Olaortua Collaborators: Miriam Izquierdo Sans Funding agency: Ministerio Economía, Industria y Competitividad Funding: 36000 Reference: PTA2013-08431-I Duration: 01/08/2014 - 31/07/2017 Targeted delivery of therapeutic siRNA to Ewing sarcoma junction oncogene by traceable diamond nanocrystal - antibody conjugate DiamESTar IP: Ibane Abasolo Olaortua Collaborators: Laura Barbera Ferrando Funding agency: Instituto de Salud Carlos III Funding: 75000.64 Reference: AC14/00032 Duration: 01/01/2015 - 30/06/2019 Pagination First page « Previous page ‹ … Page 4 Page 5 Current page 6 Page 7 Page 8 Next page › Last page »
